These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 29534940)

  • 1. Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell Carcinoma.
    Giuliani J; Bonetti A
    Clin Genitourin Cancer; 2018 Jun; 16(3):e557-e562. PubMed ID: 29534940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma.
    Swallow E; Messali A; Ghate S; McDonald E; Duchesneau E; Perez JR
    J Manag Care Spec Pharm; 2018 Apr; 24(4):335-343. PubMed ID: 29578848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab in the Treatment of Metastatic Renal Cell Carcinoma: A Cost-Utility Analysis.
    Raphael J; Sun Z; Bjarnason GA; Helou J; Sander B; Naimark DM
    Am J Clin Oncol; 2018 Dec; 41(12):1235-1242. PubMed ID: 29727313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.
    Wan X; Zhang Y; Tan C; Zeng X; Peng L
    JAMA Oncol; 2019 Apr; 5(4):491-496. PubMed ID: 30789633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors.
    Giuliani J; Bonetti A
    Anticancer Res; 2019 Jul; 39(7):3961-3965. PubMed ID: 31262928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma.
    Sarfaty M; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
    Eur Urol; 2018 Apr; 73(4):628-634. PubMed ID: 28807351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
    Engel Ayer Botrel T; Datz Abadi M; Chabrol Haas L; da Veiga CRP; de Vasconcelos Ferreira D; Jardim DL
    J Med Econ; 2021; 24(1):291-298. PubMed ID: 33538203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma.
    Giuliani J; Bonetti A
    Clin Genitourin Cancer; 2019 Apr; 17(2):e258-e262. PubMed ID: 30545674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NICE Guidance - Nivolumab for previously treated advanced renal cell carcinoma: © NICE (2017) Nivolumab for previously treated advanced renal cell carcinoma.
    BJU Int; 2018 Sep; 122(3):362-370. PubMed ID: 30187657
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
    Watson TR; Gao X; Reynolds KL; Kong CY
    JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor inhibitors in first-line for metastatic colorectal cancer with ras wild-type: a perspective based on pharmacological costs.
    Giuliani J; Bonetti A
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):243-248. PubMed ID: 28649886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma.
    Ishihara H; Takagi T; Kondo T; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Med Oncol; 2019 Mar; 36(4):35. PubMed ID: 30879157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations.
    Giuliani J; Remo A; Bonetti A
    Expert Rev Pharmacoecon Outcomes Res; 2017 Feb; 17(1):5-8. PubMed ID: 27830967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Int J Clin Oncol; 2020 Apr; 25(4):705-712. PubMed ID: 31858306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Wallis CJD; Klaassen Z; Bhindi B; Ye XY; Chandrasekar T; Farrell AM; Goldberg H; Boorjian SA; Leibovich B; Kulkarni GS; Shah PS; Bjarnason GA; Heng DYC; Satkunasivam R; Finelli A
    Eur Urol; 2018 Sep; 74(3):309-321. PubMed ID: 29656851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis.
    Hale P; Hahn AW; Rathi N; Pal SK; Haaland B; Agarwal N
    J Geriatr Oncol; 2019 Jan; 10(1):149-154. PubMed ID: 29861146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
    De Giorgi U; Cartenì G; Giannarelli D; Basso U; Galli L; Cortesi E; Caserta C; Pignata S; Sabbatini R; Bearz A; Buti S; Lo Re G; Berruti A; Bracarda S; Cognetti F; Rastelli F; Fornarini G; Porta C; Turci D; Sternberg CN; Procopio G;
    BJU Int; 2019 Jan; 123(1):98-105. PubMed ID: 29956884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
    Zarrabi K; Wu S
    Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data.
    Hinata N; Yonese J; Masui S; Nakai Y; Shirotake S; Tatsugami K; Inamoto T; Nozawa M; Ueda K; Etsunaga T; Osawa T; Uemura M; Kimura G; Numakura K; Yamana K; Miyake H; Fukasawa S; Ochi K; Kaneko H; Uemura H
    Int J Clin Oncol; 2020 Aug; 25(8):1533-1542. PubMed ID: 32519026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.